Department Pathology and Medical Biology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.
Oral Oncol. 2022 Dec;135:106227. doi: 10.1016/j.oraloncology.2022.106227. Epub 2022 Nov 3.
Head and neck squamous cell carcinoma (HNSCC) is an immunogenic cancer type, and tumor associated macrophages (TAMs) are a major component of the tumor microenvironment (TME). In this systematic review and meta-analysis, studies assessing tumor infiltration with CD68+, iNOS+, HLA-DR+, CD11b+, CD163+, CD206+, and CD204+TAMs were included, and correlation to survival hazard was studied. A low number of CD68+TAMs correlated to better overall survival (OS) in multivariate analysis (HR 1.36 95 %CI (1.07-1.72) P = .01). CD68+TAMs did not correlate to disease free survival (DFS), disease specific survival (DSS), progression free survival (PFS), or recurrence free survival (RFS). A low number of CD163+TAMs correlated to better OS in uni- and multivariate analysis (resp. HR 2.65 95 %CI (1.57-4.46) P = .01 and HR 2.42 95 %CI (1.72-3.41) P < .001). A low number of CD163+TAMs also correlated to better DFS and PFS, whereas a low number of CD204+TAMs only correlated to PFS. While IHC analysis of pan macrophage marker CD68 and M2-like marker CD163 both show prognostic utility in OS, CD163 is a stronger prognosticator, as indicated by multivariate meta-analysis. CD163+TAMs also correlate to DFS and PFS; outcomes that are more relevant to patients, thus showing promising results for future clinical implementation.
头颈部鳞状细胞癌 (HNSCC) 是一种免疫原性癌症类型，肿瘤相关巨噬细胞 (TAMs) 是肿瘤微环境 (TME) 的主要组成部分。在这项系统评价和荟萃分析中，评估了 CD68+、iNOS+、HLA-DR+、CD11b+、CD163+、CD206+和 CD204+TAMs 浸润肿瘤的研究，并研究了与生存危险的相关性。多变量分析中，CD68+TAMs 数量较少与总生存期 (OS) 更好相关 (HR 1.36 95%CI (1.07-1.72) P=0.01)。CD68+TAMs 与无病生存期 (DFS)、疾病特异性生存期 (DSS)、无进展生存期 (PFS) 或无复发生存期 (RFS) 无关。低数量的 CD163+TAMs 与单变量和多变量分析中的 OS 更好相关（分别为 HR 2.65 95%CI (1.57-4.46) P=0.01 和 HR 2.42 95%CI (1.72-3.41) P<0.001）。低数量的 CD163+TAMs 也与更好的 DFS 和 PFS 相关，而低数量的 CD204+TAMs 仅与 PFS 相关。虽然 CD68（一种巨噬细胞标志物）和 CD163（一种 M2 样标志物）的 IHC 分析均显示出对 OS 的预后作用，但 CD163 作为一种更强的预后标志物，这一点通过多变量荟萃分析得到了证实。CD163+TAMs 也与 DFS 和 PFS 相关；这些结果与患者更相关，因此为未来的临床应用提供了有希望的结果。
